Ainos, Inc.

NasdaqCM:AIMD Stock Report

Market Cap: US$14.1m

Ainos Future Growth

Future criteria checks 0/6

We currently don't have sufficient analyst coverage to forecast growth and revenue for Ainos.

Key information

n/a

Earnings growth rate

n/a

EPS growth rate

Tech earnings growth11.8%
Revenue growth raten/a
Future return on equityn/a
Analyst coverage

None

Last updatedn/a

Recent future growth updates

No updates

Recent updates

Analysis Article • Dec 12

Ainos (NASDAQ:AIMD) Has Debt But No Earnings; Should You Worry?

The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...
Analysis Article • Aug 29

Ainos (NASDAQ:AIMD) Is Carrying A Fair Bit Of Debt

Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...
Analysis Article • Mar 10

We Think Ainos (NASDAQ:AIMD) Has A Fair Chunk Of Debt

The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...
Analysis Article • Aug 28

Here's Why Ainos (NASDAQ:AIMD) Can Afford Some Debt

The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...
Analysis Article • May 15

Here's Why Ainos (NASDAQ:AIMD) Can Afford Some Debt

Warren Buffett famously said, 'Volatility is far from synonymous with risk.' So it might be obvious that you need to...
Seeking Alpha • Sep 30

Ainos rises 50% on positive data from animal study trial of Veldona to treat COVID-19

Ainos (NASDAQ:AIMD) has surged 50% premarket after the company said its low-dose oral interferon (IFN)-alpha formulation Veldona showed a positive effect on lungs infected with the the Omicron variant of the coronavirus by regulating the immune response, thereby expediting recovery of hamsters. The copany had filed an application to the U.S. Food and Drug Administration (FDA) seeking clearance to conduct a phase 2 trial for the drug. The study tested the effectiveness of Veldona over a sixteen-day course and compared with hamsters in the placebo group. The hamsters in the group receiving Veldona showed resistance to body weight loss immediately after infection, then showed a better recovery trend in the following three days.
Seeking Alpha • Aug 24

Ainos stock rises on FDA filing for starting phase 2 trial of Veldona for COVID-19

Ainos (NASDAQ:AIMD) filed an application to the U.S. Food and Drug Administration (FDA) seeking clearance to conduct a phase 2 trial of its low-dose oral interferon (IFN)-alpha formulation Veldona to treat mild symptoms related to COVID-19. Earlier in August, the company said that it had started a phase 2 trial of Veldona in patients with mild COVID-19 in Taiwan, following results from preclinical studies. "Our Company is investigating whether impaired type I IFN could be related to persistent high blood viral loads and inflammatory responses in COVID-19 cases," said Chairman President and CEO Chun-Hsien Tsai. AIMD +5.28% to $2.59 premarket Aug. 24
Seeking Alpha • Aug 15

Amarillo Biosciences GAAP EPS of -$0.01, revenue of $636.62M

Amarillo Biosciences press release (NASDAQ:AIMD): Q2 GAAP EPS of -$0.01. Revenue of $636.62M (+213.6% Y/Y).

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Ainos has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.

Earnings and Revenue Growth Forecasts

NasdaqCM:AIMD - Analysts future estimates and past financials data (USD Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
3/31/20260-14-4-4N/A
12/31/20250-15-5-5N/A
9/30/20250-15-5-5N/A
6/30/20250-16-5-5N/A
3/31/20250-15-6-6N/A
12/31/20240-15-6-6N/A
9/30/20240-16-6-6N/A
6/30/20240-15-6-6N/A
3/31/20240-15-5-5N/A
12/31/20230-14-5-5N/A
9/30/20231-10-4-4N/A
6/30/20233-15-4-4N/A
3/31/20233-14-4-3N/A
12/31/20224-14-4-3N/A
9/30/20223-13-4-3N/A
6/30/20221-7-3-3N/A
3/31/20221-5-3-2N/A
12/31/20211-4-1-1N/A
9/30/20211-3-1-1N/A
6/30/20210-200N/A
3/31/20210-2-1-1N/A
12/31/20200-1-10N/A
9/30/20200-1-1-1N/A
6/30/20200-1-1-1N/A
3/31/20200-2-1-1N/A
12/31/20190-2N/A-1N/A
9/30/20190-2N/A-1N/A
6/30/20190-2N/A-1N/A
3/31/20190-2N/A-1N/A
12/31/20180-1N/A-1N/A
9/30/20180-1N/A-1N/A
6/30/20180-1N/A-1N/A
3/31/20180-1N/A0N/A
12/31/20170-1N/A0N/A
9/30/20170-1N/A0N/A
6/30/20170-1N/A0N/A
3/31/2017N/A-1N/A-1N/A
12/31/2016N/A-1N/A-1N/A
9/30/20160-1N/A-1N/A
6/30/20160-1N/A0N/A
3/31/2016N/A-1N/A0N/A
12/31/2015N/A-1N/A0N/A
9/30/2015N/A3N/A0N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: Insufficient data to determine if AIMD's forecast earnings growth is above the savings rate (3.5%).

Earnings vs Market: Insufficient data to determine if AIMD's earnings are forecast to grow faster than the US market

High Growth Earnings: Insufficient data to determine if AIMD's earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: Insufficient data to determine if AIMD's revenue is forecast to grow faster than the US market.

High Growth Revenue: Insufficient data to determine if AIMD's revenue is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if AIMD's Return on Equity is forecast to be high in 3 years time

Discover growth companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/06/14 16:46
End of Day Share Price 2026/06/12 00:00
Earnings2026/03/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Ainos, Inc. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.